» Articles » PMID: 32267550

Dihydromyricetin Protects the Liver Via Changes in Lipid Metabolism and Enhanced Ethanol Metabolism

Overview
Specialty Psychiatry
Date 2020 Apr 9
PMID 32267550
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Excess alcohol (ethanol, EtOH) consumption is a significant cause of chronic liver disease, accounting for nearly half of the cirrhosis-associated deaths in the United States. EtOH-induced liver toxicity is linked to EtOH metabolism and its associated increase in proinflammatory cytokines, oxidative stress, and the subsequent activation of Kupffer cells. Dihydromyricetin (DHM), a bioflavonoid isolated from Hovenia dulcis, can reduce EtOH intoxication and potentially protect against chemical-induced liver injuries. But there remains a paucity of information regarding the effects of DHM on EtOH metabolism and liver protection. As such, the current study tests the hypothesis that DHM supplementation enhances EtOH metabolism and reduces EtOH-mediated lipid dysregulation, thus promoting hepatocellular health.

Methods: The hepatoprotective effect of DHM (5 and 10 mg/kg; intraperitoneal injection) was evaluated using male C57BL/6J mice and a forced drinking ad libitum EtOH feeding model and HepG2/VL-17A hepatoblastoma cell models. EtOH-mediated lipid accumulation and DHM effects against lipid deposits were determined via H&E stains, triglyceride measurements, and intracellular lipid dyes. Protein expression of phosphorylated/total proteins and serum and hepatic cytokines was determined via Western blot and protein array. Total NAD /NADH Assay of liver homogenates was used to detect NAD + levels.

Results: DHM reduced liver steatosis, liver triglycerides, and liver injury markers in mice chronically fed EtOH. DHM treatment resulted in increased activation of AMPK and downstream targets, carnitine palmitoyltransferase (CPT)-1a, and acetyl CoA carboxylase (ACC)-1. DHM induced expression of EtOH-metabolizing enzymes and reduced EtOH and acetaldehyde concentrations, effects that may be partly explained by changes in NAD . Furthermore, DHM reduced the expression of proinflammatory cytokines and chemokines in sera and cell models.

Conclusion: In total, these findings support the utility of DHM as a dietary supplement to reduce EtOH-induced liver injury via changes in lipid metabolism, enhancement of EtOH metabolism, and suppressing inflammation responses to promote liver health.

Citing Articles

Molecular Mechanism of Vine Tea Dihydromyricetin Extract on Alleviating Glucolipid Metabolism Disorder in Mice: Based on Liver RNA-Seq and TLR4/MyD88/NF-κB Pathway.

Zhou X, Liu X, Yi Y, Chen S, Zhang Y, Fan W Int J Mol Sci. 2025; 26(5).

PMID: 40076792 PMC: 11900051. DOI: 10.3390/ijms26052169.


Improving the solubility of pseudo-hydrophobic chemicals through co-crystal formulation.

Janilkarn-Urena I, Tse A, Lin J, Tafolla-Aguirre B, Idrissova A, Zhang M PNAS Nexus. 2025; 4(1):pgaf007.

PMID: 39850078 PMC: 11756387. DOI: 10.1093/pnasnexus/pgaf007.


Dihydromyricetin: an emerging compound with comprehensive effects on multiple systems.

He C, Chen Y, Xie J, Luo M, Fisher D, Hien N Front Pharmacol. 2025; 15():1488003.

PMID: 39830336 PMC: 11739078. DOI: 10.3389/fphar.2024.1488003.


Gegen-Sangshen oral liquid and its active fractions mitigate alcoholic liver disease in mice through repairing intestinal epithelial injury and regulating gut microbiota.

Wei S, Li M, Zhao L, Wang T, Wu K, Yang J Chin Med. 2024; 19(1):175.

PMID: 39716295 PMC: 11667864. DOI: 10.1186/s13020-024-01049-y.


Design, synthesis, and biological activity evaluation of dihydromyricetin derivatives against SARS-CoV-2-Omicron virus.

Wu C, Jiang Q, Zhong H, Zhou X, Liu L, Pan T J Enzyme Inhib Med Chem. 2024; 39(1):2390909.

PMID: 39206852 PMC: 11363738. DOI: 10.1080/14756366.2024.2390909.


References
1.
Xiang D, Wang C, Wang W, Shi C, Xiong W, Wang M . Gastrointestinal stability of dihydromyricetin, myricetin, and myricitrin: an in vitro investigation. Int J Food Sci Nutr. 2017; 68(6):704-711. DOI: 10.1080/09637486.2016.1276518. View

2.
Keegan A, Martini R, Batey R . Ethanol-related liver injury in the rat: a model of steatosis, inflammation and pericentral fibrosis. J Hepatol. 1995; 23(5):591-600. DOI: 10.1016/0168-8278(95)80067-0. View

3.
Castaneda F, Kinne R . Ethanol treatment of hepatocellular carcinoma: high potentials of low concentrations. Cancer Biol Ther. 2004; 3(5):430-3. DOI: 10.4161/cbt.3.5.806. View

4.
Yilmaz Y, Eren F . Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology. Eur J Gastroenterol Hepatol. 2018; 31(1):43-46. DOI: 10.1097/MEG.0000000000001240. View

5.
Dhanda A, Lee R, Collins P, McCune C . Molecular targets in the treatment of alcoholic hepatitis. World J Gastroenterol. 2012; 18(39):5504-13. PMC: 3482636. DOI: 10.3748/wjg.v18.i39.5504. View